Metastases to liver – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 13 Jun 2026 04:02:57 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Metastases to liver – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Preoperative Immunotherapy with Atezolizumab and Tiragolumab for Patients with Colorectal Liver Metastases https://clinicaltrials.eu/trial/study-on-preoperative-immunotherapy-with-atezolizumab-and-tiragolumab-for-patients-with-colorectal-liver-metastases/ Wed, 29 Apr 2026 15:00:36 +0000 https://clinicaltrials.eu/trial/study-on-preoperative-immunotherapy-with-atezolizumab-and-tiragolumab-for-patients-with-colorectal-liver-metastases/ This clinical trial is focused on studying a treatment for patients with colorectal liver metastases, which is a condition where cancer from the colon or rectum spreads to the liver. The treatment being tested involves two medications: atezolizumab, also known by its brand name Tecentriq, and tiragolumab. Atezolizumab is a type of immunotherapy, which means it helps the body’s immune system fight cancer. Tiragolumab is another immunotherapy drug that works in a similar way. Both medications are given as a solution through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of this study is to see how well these medications work in shrinking the tumors before surgery. Patients will receive the treatment for a period of time before their scheduled surgery to remove the cancer. The study will monitor the response of the tumors to the treatment and any side effects that may occur. The goal is to determine if the combination of atezolizumab and tiragolumab can improve the chances of successful surgery by reducing the size of the tumors.

Throughout the study, patients will have regular check-ups and tests to assess their health and the effectiveness of the treatment. These tests may include imaging scans like PET-CT or PET-MRI, which help doctors see how the cancer is responding to the treatment. The study will also look at the rate of successful surgeries and any complications that might arise after the treatment. The trial is expected to continue until 2026, with recruitment starting in 2024.

]]> Study on the Effects of Atezolizumab, Bevacizumab, Oxaliplatin, and Capecitabine in Patients with Colorectal Cancer and Liver Metastasis https://clinicaltrials.eu/trial/study-on-the-effects-of-atezolizumab-bevacizumab-oxaliplatin-and-capecitabine-in-patients-with-colorectal-cancer-and-liver-metastasis/ Wed, 29 Apr 2026 15:00:00 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-atezolizumab-bevacizumab-oxaliplatin-and-capecitabine-in-patients-with-colorectal-cancer-and-liver-metastasis/ This clinical trial is focused on studying a type of cancer known as colorectal cancer that has spread mainly to the liver. The study aims to evaluate the effectiveness and safety of combining several treatments for this condition. The treatments being tested include a standard chemotherapy regimen called XELOX, which is a combination of two drugs, capecitabine and oxaliplatin. Additionally, the study involves the use of targeted therapies, specifically bevacizumab (also known as Avastin) and atezolizumab (also known as Tecentriq or RO5541267), which is an immune checkpoint inhibitor. These treatments are combined with a specialized form of radiation therapy that targets the liver.

The purpose of the study is to assess how well these combined treatments work in preventing the cancer from getting worse over a period of nine months. Participants in the study will receive these treatments through intravenous infusions, which means the medication is delivered directly into the bloodstream through a vein. The study will monitor the participants’ health and the progression of their cancer over time to gather information on the effectiveness and any potential side effects of the treatment combination.

This trial is designed to provide valuable insights into the potential benefits of combining chemotherapy, targeted therapy, immunotherapy, and internal radiation therapy for patients with liver-dominant metastatic colorectal cancer. The study is open-label, meaning both the researchers and participants know which treatments are being administered. The ultimate goal is to improve treatment outcomes for patients with this specific type of cancer.

]]> Study on Oxaliplatin and Irinotecan for Patients with Metastatic Colorectal Cancer in the Liver https://clinicaltrials.eu/trial/study-on-oxaliplatin-and-irinotecan-for-patients-with-metastatic-colorectal-cancer-in-the-liver/ Wed, 29 Apr 2026 14:58:05 +0000 https://clinicaltrials.eu/trial/study-on-oxaliplatin-and-irinotecan-for-patients-with-metastatic-colorectal-cancer-in-the-liver/ This clinical trial is focused on studying metastatic colorectal cancer, which is a type of cancer that starts in the colon or rectum and spreads to the liver. The study is exploring the use of a treatment called oxaliplatin, which is a medication given as a solution for infusion, meaning it is administered directly into the bloodstream. The trial is comparing two methods of delivering oxaliplatin: one is through the veins, known as intravenous administration, and the other is directly into the arteries, known as intra-arterial administration. The study also involves additional treatments, including a combination of chemotherapy drugs called LV5FU2 and sometimes irinotecan, along with targeted therapy, which is a type of treatment that targets specific cancer cells.

The purpose of the study is to compare how well the cancer responds to these different methods of treatment. Participants will receive either the intravenous or intra-arterial administration of oxaliplatin, along with the other treatments, to see which method is more effective in controlling the cancer. The study will monitor the progression of the disease using imaging techniques and clinical evaluations to determine how long the cancer can be kept from worsening. The trial will also assess the side effects of the treatments and their impact on the participants’ quality of life.

Throughout the study, participants will undergo regular check-ups and imaging tests to track the cancer’s response to the treatment. The trial aims to provide valuable information on the best approach to treating metastatic colorectal cancer that has spread to the liver, potentially improving outcomes for patients with this condition. The study is expected to continue until 2026, allowing researchers to gather comprehensive data on the effectiveness and safety of the treatments being tested.

]]> Study on Melphalan, Ipilimumab, and Nivolumab for Patients with Uveal Melanoma Liver Metastases https://clinicaltrials.eu/trial/study-on-melphalan-ipilimumab-and-nivolumab-for-patients-with-uveal-melanoma-liver-metastases/ Wed, 29 Apr 2026 14:29:57 +0000 https://clinicaltrials.eu/trial/study-on-melphalan-ipilimumab-and-nivolumab-for-patients-with-uveal-melanoma-liver-metastases/ This clinical trial is focused on studying a type of cancer called Uveal Melanoma, which can spread to the liver, known as liver metastases. The study is investigating the effectiveness of a treatment method called Percutaneous Hepatic Perfusion (PHP) combined with two medications, Ipilimumab and Nivolumab, compared to using Ipilimumab and Nivolumab alone. Ipilimumab and Nivolumab are medications that help the immune system fight cancer cells. PHP is a procedure where a high dose of chemotherapy is delivered directly to the liver while the rest of the body is protected from the effects of the drug.

The purpose of this study is to evaluate how well patients with uveal melanoma liver metastases respond to these treatments. Participants will be randomly assigned to receive either the combination of PHP with Ipilimumab and Nivolumab or just Ipilimumab and Nivolumab. The study will monitor the progression of the disease, which means checking if the cancer is growing or spreading, and will also look at the overall health and quality of life of the participants.

Throughout the study, participants will receive regular treatments and check-ups to monitor their health and the effects of the treatment. The study aims to provide valuable information on whether adding PHP to the treatment plan can improve outcomes for patients with this type of cancer. The trial is expected to continue for several years to gather comprehensive data on the effectiveness and safety of the treatments being tested.

]]> Study on the Effectiveness of Floxuridine and Drug Combination for Patients with Unresectable Colorectal Liver Metastases https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-floxuridine-and-drug-combination-for-patients-with-unresectable-colorectal-liver-metastases/ Wed, 29 Apr 2026 14:27:45 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-floxuridine-and-drug-combination-for-patients-with-unresectable-colorectal-liver-metastases/ This clinical trial is focused on studying treatments for colorectal liver metastases, which are cancerous growths in the liver that originate from colorectal cancer. The study will compare two treatment approaches: one group will receive a combination of hepatic arterial infusion pump (HAIP) chemotherapy and systemic therapy, while the other group will receive systemic therapy alone. The systemic therapy includes medications such as irinotecan hydrochloride, oxaliplatin, capecitabine, fluorouracil, calcium folinate, bevacizumab, and dexamethasone acetate. Additionally, floxuridine will be used in the HAIP chemotherapy group. The purpose of the study is to determine if the combination of HAIP chemotherapy and systemic therapy can improve survival in patients with initially unresectable colorectal liver metastases compared to systemic therapy alone.

Participants in the study will be randomly assigned to one of the two treatment groups. The study will last for up to 52 weeks, during which participants will receive their assigned treatments. The treatments will be administered through different methods, including intravenous (directly into a vein) and intra-arterial (directly into an artery) routes, depending on the specific medication. Some medications, like capecitabine, will be taken orally. The study will monitor the participants’ health and response to the treatments throughout the trial period.

The trial aims to assess various outcomes, including overall survival, progression-free survival, and the rate at which the cancer can be surgically removed after treatment. It will also evaluate the quality of life of participants and any side effects or complications that may arise from the treatments. The study will help determine the effectiveness of combining HAIP chemotherapy with systemic therapy in treating colorectal liver metastases.

]]> Study on Treatment for Colorectal Liver Metastases Using Heparin, Dexamethasone, and Floxuridine for Patients with Heavy Tumor Burden https://clinicaltrials.eu/trial/study-on-treatment-for-colorectal-liver-metastases-using-heparin-dexamethasone-and-floxuridine-for-patients-with-heavy-tumor-burden/ Wed, 29 Apr 2026 14:27:21 +0000 https://clinicaltrials.eu/trial/study-on-treatment-for-colorectal-liver-metastases-using-heparin-dexamethasone-and-floxuridine-for-patients-with-heavy-tumor-burden/ This clinical trial is focused on studying treatments for Colorectal Liver Metastases, which are cancerous growths that have spread to the liver from the colon or rectum. The study will use several medications, including Heparin, a blood thinner, Dexamethasone Acetate, a type of steroid, Dexamethasone Sodium Phosphate, another form of steroid, and Floxuridine, a chemotherapy drug. The purpose of the study is to evaluate the effectiveness of these treatments in improving overall survival over a period of two years.

Participants in the study will receive one or more of these medications through an intravenous infusion, which means the medicine is delivered directly into the bloodstream. The study will compare the effects of these medications on the participants’ health, including their ability to control the cancer and improve quality of life. Some participants may receive a placebo, which is a substance with no active medication, to help researchers understand the true effects of the treatments being tested.

The study will last for several years, with regular check-ups and assessments to monitor the participants’ health and response to the treatment. The goal is to determine if these medications can help patients live longer and manage their cancer more effectively. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

]]> Study on Fluorescence-Guided Surgery for Colorectal Liver Metastases Using SGM-101 and Indocyanine Green for Patients with Colorectal Cancer https://clinicaltrials.eu/trial/study-on-fluorescence-guided-surgery-for-colorectal-liver-metastases-using-sgm-101-and-indocyanine-green-for-patients-with-colorectal-cancer/ Wed, 29 Apr 2026 14:23:34 +0000 https://clinicaltrials.eu/trial/study-on-fluorescence-guided-surgery-for-colorectal-liver-metastases-using-sgm-101-and-indocyanine-green-for-patients-with-colorectal-cancer/ This clinical trial is focused on studying a condition known as colorectal liver metastases, which occurs when cancer cells from the colon or rectum spread to the liver. The study is exploring a new approach to help surgeons see these cancerous areas more clearly during surgery. This involves using a special treatment called SGM-101, which is a type of protein designed to attach to cancer cells and make them glow under a special light. This glow helps doctors identify and remove the cancer more effectively. The study also uses a substance called Indocyanine Green, which is another type of dye that helps highlight the cancerous areas.

The purpose of the study is to see if using both SGM-101 and Indocyanine Green together can improve the way doctors find and remove liver metastases from colorectal cancer during surgery. Participants in the study will receive these substances through an injection before their surgery. During the operation, the surgeons will use special imaging techniques to see how well these substances highlight the cancerous areas. This will help them decide the best way to remove the cancer.

The study will follow participants through their surgical procedure and assess how well the substances work in highlighting the cancer. The goal is to determine if this method can make surgeries more successful by ensuring that all cancerous tissue is removed. This could potentially lead to better outcomes for patients with colorectal liver metastases. The study will also gather feedback from both the surgeons and the patients to understand their experiences with this new approach.

]]>